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ABSTRACT
Cardiovascular disease (CVD) has taken up to average 30% of death diagnoses in the
world. Prevalent attempts of physicians to treat this disease came down to focus on using
drugs with their specific mechanism of action. Since the method only cures the symptoms
and need to be pharmacologically monitored, physicians and scientists have been struggling to find other treatment strategies. This problem led us to search for another substance
dealing with CVD via preventive therapy, which does not require such close monitoring
by physicians in its use. The answer relies on using L-citrulline as potential therapeutics
in treating and preventing CVDs. This compound, found mostly in Citrus sp., contains
chemical traits that could affect other bodily substances with its metabolic pathways. It
has several functions, but boosting NO production is the dominant one in the cardiovascular system. By enhancing NO bioavailability, it suppresses the risk of having myocardial
oxidative stress due to ischemia, cardiac pressure-overload, and post-infarct reperfusion.
Thus, understanding of L-citrulline effects on endothelial NOS pathway in the generation
of NO and its uncoupling mechanisms could be used as a foundation in developing alternative treatment and prevention of oxidative stress-induced CVD.
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INTRODUCTION
Cardiovascular disease (CVD) has been the most common
nationwide cause of death. It accounts for average
30% ultimate cause of death in both developed and
developing countries. The era of rapid industrialization
and urbanization has promoted higher emergent of the
diseases, with some examples such as pathological
cardiac hypertrophy, myocardial infarction, and cardiac
valve lesions. Risk factors increasing probability of
suffering CVDs include the molecular scope of genetics
into wide exposure of environmental factors (Loscalzo
& Harrison, 2013).
Physicians’ attempts to relieve CVDs have come down
into usage of specific pharmacological strategies, such as
antihypertensive agents or diuretics. Although they are
often deployed to treat CVDs with such low therapeutic
index, their amounts in blood plasma must be controlled
very carefully to minimize any adverse effects (Katzung
et al., 2015). Since the method only cured symptoms
and needed to be pharmacologically monitored,
physicians and scientists have been struggling to find
other treatment strategies. This problem led us to search
for another substance dealing with CVD via preventive
therapy, which does not require such a close monitoring
by physicians in its use. The proximate and ultimate
answer for these problems is yes. It is L-citrulline.
L-citrulline is known to have potential therapeutics in
relieving CVDs. Following discussions of L-citrulline
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are explained further into its molecular structure,
biochemistry, pharmacology, physiology, as well as its
utilization in treating cardiovascular system.
L-citrulline is a non-essential amino acid classified
specifically as a non-protein monomer (Kaore & Kaore,
2014). It means that L-citrulline cannot be used as raw
material in cellular protein synthesis, except that it
emerges as post-translational modification or Golgi’s
products. L-citrulline does not charge with tRNA
normally as it does not correspond within the known
20 types of amino acids. Moreover, it is discovered
in muskmelons, squashes, gourds, cucumbers, and
pumpkins, as well as watermelons. Watermelons or
Citrus vulgaris are the ones contain lots of L-citrulline,
which constitutes approximately 2.1 mg per gram of fresh
weight (Frank et al., 2017). Schematic representation of
watermelon functions can be seen in Figure 1.
L-citrulline may serve as antioxidant that prevents DNA
damage-induced oxidative stress and reticuloendothelial
system over activity. L-citrulline could also enhance
muscle protein synthesis, reduce gastrointestinal
tract injury during exercise, and improve bloodtissue perfusion. In this review, focus of L-citrulline
activities would be in the cardiovascular system. Any
supplementation of L-citrulline for human could be
obtained through chemical industries, genetically
modified microorganisms, or enzymatic reaction (Jiang
et al., 2017).

L-Citrulline as Alternative Pharmacological

Pharm Sci Res, Vol 5 No 2, 2018

73

Figure 1. Watermelon (Citrus vulgaris) contains citrulline that promotes vasodilation,
antioxidation, anti-inflammation, and healthy hepato-hematological functions Hong M et al., 2015.
COX-2: cyclooxygenase 2, CRP: c-reactive protein, CVD: cardiovascular disease, HDL: high density
lipoprotein, LDL: low density lipoprotein, NO: nitric oxide, NOS: nitric oxide synthase, RelA: NFkappa-B p65 subunit, TC: total cholesterol, TG: triglyceride
Biochemistry of L-citrulline
Chemical Characteristics of L-citrulline
L-citrulline is a non-protein amino acid with C6H13N3O3
alpha-structured configuration withmolecular mass
175.19 Dalton. Its high solubility in water makes it
perfect for oral administration via aqueous solution.
Available in white powder form and alkalized-smell,
its natural structure is often discovered in levorotatory
stereoisomerization. Considering its hydrophilic custom,
high intake of L-citrulline orally might cause osmotic
diarrhea (Kaore & Kaore, 2014). Molecular structure of
L-citrulline can be seen in Figure 2.

Figure 2. Molecular structure of L-citrulline
(Kaore S et al., 2014)
Metabolism and Biosynthesis of L-citrulline
L-citrulline is biosynthesized through nitric oxide and
urea cycles. Urea cycle covers up to 90% production of
L-citrulline in hepatocytes (Frank et al., 2017). Arginine
is first transformed into ornithine by arginase, releasing
urea into blood plasma to be further cleared via kidneys
(Kaore & Kaore, 2014). Ornithine then combined with
carbamoyl phosphate as constituents of ammonia to
form citrulline by the enzymatic activity of ornithine
carbamoyltransferase (Frank et al., 2017). Besides,
citrulline could be metabolized back into arginine using
argininosuccinate as intermediates by argininosuccinate
synthase and lyase (Mori et al., 2015).
Another process involved in the generation of
L-citrulline is the nitric oxide cycle in blood vessels

which covers up 10% production of plasma L-citrulline
(Frank et al., 2017). Direct transformation of arginine
into citrulline using nitric oxide synthase gives out NO
into plasma. Reverse metabolism from citrulline into
arginine is associated with the same pathway using
argininosuccinate as biosynthetic intermediate (Jiang et
al., 2017). In double-blind randomized research crossover design, supplementation of L-citrulline could
remove any excess ammonia accumulation in blood,
alleviating any central fatigue in athletes (Chen et al.,
2016). Detail schematic metabolism of L-citrulline can
be seen in Figure 3 and 4.
Although nitric oxide cycle only constitutes tiny part
of L-citrulline production, it gives the biggest point
of information regarding mechanisms of L-citrulline
towards cardiovascular system. Studies conducted to
prove this hypothesis explained that consumption of
Citrus vulgaris regularly would resist cellular damage
due to its antioxidative activity. As Citrus sp. elevates
plasma concentration of L-citrulline, it encourages the
bioavailability of NO gas throughout systemic and
pulmonary blood vessels. This condition provide basis
for applying L-citrulline in promoting cardiovascular
health (Hong et al., 2015).
Physiological Mechanisms
Cardiovascular System

of

L-citrulline

in

L-citrulline: Nitric Oxide Production Booster
NO is a rapidly diffusing gaseous molecule that is
released at several locations, such as vascular endothelial
cells, neurons, and glial cells. It acts as vasodilator by
relaxing vessels’ smooth muscle. Production of NO gas
is done by nitric oxide synthase using L-arginine as
primary substrate in the NO cycle. L-citrulline, in this
NO cycle, could be in paradoxical functions: precursor of
L-arginine or byproducts of L-arginine metabolism while
making NO as well (Lorin et al., 2014). Supplementation
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Figure 3. L-citrulline in metabolic pathways: urea and nitric oxide cycle (Frank et al., 2017).

Figure 4. L-citrulline metabolism in liver, enterocytes, and kidneys.
Note that L-citrulline could be used as biomarker (Kaore et al., 2014).
of L-citrulline orally increases plasma concentration of
L-arginine. Additionally, arginine is then metabolized
back into citrulline via either urea or nitric oxide cycle
(Kurauchi et al., 2017). Beside the use of L-citrulline
as single agent, the combination of L-arginine and
L-citrulline supplementation would further increase
the amount of plasma citrulline (Suzuki et al., 2017).
Metabolic balance manages the whole concentration of
arginine and citrulline itself in blood plasma. Graphical
presentation between L-citrulline administration and
amount of plasma citrulline is explained in Figure 5.
In vascular endothelium, NO is released by endothelial
nitric oxide synthase (eNOS) involving L-arginine and
L-citrulline as substrate and product respectively (Incalza
et al., 2017). Adequate L-citrulline supplementation
gradually activates NO production due to recycling of
L-citrulline into L-arginine. As a result, L-citrulline
ISSN 2407-2354

would indirectly increase NO levels in plasma (Mori
et al., 2015). Furthermore, NO does not exist long
enough in plasma soon after its release. Its maximum
distance of diffusion is 300 µm with half-life of 0.05-1.8
milliseconds (Mori et al., 2015). Relationship between
L-citrulline and plasma NO is explained in Figure 6.
Effects of L-citrulline on Plasma Amino Acids and
other Substances
Not only L-citrulline increase nitric oxide levels in blood,
but also it reduces plasma GSH which then dramatically
decrease the degradation of NO by oxidation. As a
matter of fact, serum nitrite (NO2-) concentration elevate
significantly (Frank et al., 2017). NO2- ion would be
reduced to become NO under ischemic condition (Kaore
& Kaore, 2014). Furthermore, L-citrulline affects certain
substances in plasma; for example, glutamine, ornithine,
and arginine. Arginine is transformed into L-citrulline

L-Citrulline as Alternative Pharmacological

Figure 5. Plasma concentration-time profile of
citrulline followed by continuous intravenous
infusion after citrulline bolus administration. For
comparison, citrulline plasma levels under similar
procedures without citrulline treatments
(Barr F et al., 2007).
to generate ATP by enzymatic reaction of arginine
deiminase, ornithine transcarbamoylase, and carbamate
kinase. Because of sufficient L-citrulline is found in
blood plasma, the backward mechanisms occur, which
is the transformation of L-citrulline into arginine via
argininosuccinate synthase (ASS) and argininosuccinate
lyase (ASL) (Jiang et al., 2017).
Other amino acids are not significantly affected.
L-citrulline provides serum buffering effect through
the retention of plasma bicarbonate, for it is absorbed
as equally as the urea is excreted (Frank et al., 2017).
Since the urea is formed through urea cycle involving
L-citrulline, it is therefore needed to be cleared along
urine.
Other Functions of L-citrulline
L-citrulline is one of the potent hydroxyl radical scavengers
that prevents excessive release of superoxide anion (O2-)
as oxidative stress may happen in any ischemic tissues.
L-citrulline could also become biomarker for certain
inflammation, such as that citrullinated joint protein
prone to autoantibodies attack in rheumatoid arthritis.
(Kaore & Kaore, 2014) L-citrulline is also considered to
be a powerful anabolic amino acid because it increases
the rate of muscle protein synthesis. Therefore, weight
gain is observed with massive reconstruction in muscular
system (Jiang et al., 2017).
Pharmacological Mechanisms of L-citrulline
Pharmacodynamics of L-citrulline
No direct pharmacological effect of L-citrulline towards
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Figure 6. Plasma concentration-time profile of
nitric oxide followed by continuous intravenous
infusion after citrulline bolus administration. For
comparison, citrulline plasma levels under similar
procedures without citrulline treatments.
(Barr F et al., 2007).

Figure 7. Mean blood pressure did not differ
between oral and placebo groups. P = 0.53. Mean
and standard deviation are shown for each group
for 48-hour period (Xuan C et al., 2015).
cells has been observed, but it is known to associate
closely with the pharmacodynamics of NO gas. (Kaore
& Kaore, 2014) Thus, L-citrulline balances systemic
and pulmonary vascular tone by promoting vasodilation.
This is done under the function of NO in activating
membrane signaling enzyme, that is guanylyl cyclase.
Dephosphorylation and cyclization of GTP into cGMP
intensifies the amplification of Cyclooxygenase-1/cGMP
signaling cascades that cause vessels’ smooth muscles to
relax (Mori et al., 2015).
L-citrulline is observed to relieve pulmonary arterial
hypertension since it manifests in its ability to vasodilate.
However, it induces neither systemic hypotension nor
tachycardia. Besides, that no dramatic reduction of
ISSN 2407-2354
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Table 1. Risk of pulmonary hypertension with plasma citrulline. Its relative risk of suffering
pulmonary hypertension is significantly lower with more than 37 µM plasma citrulline
treatment.14
Pulmonary
Pulmonary
Plasma Citrulline 12 h
Hypertension
Hypertension
P value
Postoperatively
Absent
Present
< 37 µmol/L
18
9
.036
37 µmol/L
12
*0

Figure 8. Pharmacokinetic modeling of IV administered bolus of citrulline, followed by
4 hours later by infusion. Bolus dose of 150 mg/kg was determined most likely to yield
4-hour trough of 80-100 µM, and infusion of 9 mg/kg/h was predicted to achieve steady
state. Note that the plasma half time is 60 minutes with dose-dependent increase along
with the added bolus dosage (Barr F et al., 2007).
mean arterial pressure is seen after administration of
L-citrulline is needed to be studied further (Heidi et
al., 2007). Association between citrulline and MAP can
be seen in Figure 7. Additionally, protective effect of
L-citrulline in relieving pulmonary hypertension risk is
explained in Table 1.
Pharmacokinetics of L-citrulline
L-citrulline is well absorbed in enteral route. Its
bioavailability in this route would be reduced to
certain concentration, since it faces first-pass effect in
the liver. Despite its conversion to other substances,
constant supplementation of oral L-citrulline marked a
linear and dose-dependent increase of plasma citrulline
(Schwedhelm et al., 2008). The optimal dosage of
L-citrulline is controlled by liver and kidneys. As a result,
latter restriction of plasma citrulline elevation occurs
after excessive supplementation of oral L-citrulline. In
addition, 83% of ingested citrulline will be taken up
by kidneys to be transformed into L-arginine (Kaore &
Kaore, 2014).
Enteral absorption of L-citrulline requires sodiumdependent cotransporter. Comparing to arginine,
L-citrulline enters bloodstream much easier from
intestinal lumen. It also provides buffering effect to other
ISSN 2407-2354

metabolic substances, especially arginine, involving urea
cycle, NO cycle, and arginine biosynthesis. That is why
it is safer and efficient to replenish plasma arginine using
L-citrulline than directly using arginine (Kurauchi et al.,
2017).
Effective dosage of L-citrulline in human is estimated
to be 40 mg/kg body weight with maximum 15 g of
L-citrulline per oral administration (Frank et al., 2017).
Clearance of plasma citrulline in kidneys is estimated
to be 0.6 L/kg/h with volume of distribution 0.9 L/
kg for 60-minute plasma half-time (Barr et al., 2007).
Maintenance of certain plasma citrulline levels needs
calculation involving citrulline infusion intravenously
(Barr et al., 2007) . Graphical presentations of L-citrulline
pharmacokinetics in one study can be seen in Figure 8.
Protection of L-citrulline Against Cardiovascular
Disease
Some CVDs has been recognized along to be related
with oxidative stress; for example, hypertrophic
cardiomyopathy, cardiac remodeling, and myocardial
infarction. They manifest in the apoptosis or necrosis
of normal cardiac myocytes. Some of these disorders
are even maintained in certain body conditions or druginduced states. Furthermore, molecular pathophysiology
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Figure 9. a) Generation of NO and L-citrulline via electron transfer in NOS
pathway. Note that the electron is taken up from NADPH domain in order to
reduce heme domain for both L-citrulline and NO synthesis. b) Uncoupling
mechanisms compensating for low BH4 cofactor and substrate L-arginine.
Note that superoxide anion replaces nitric oxide as byproducts of this pathway
(Incalza M et al., 2017).
involving the generation of reactive oxygen species
(ROS) and reactive nitrogen species (RNS) of these
diseases is the ultimate ‘culprit’. Hence, comprehension
in the ROS/RNS generation mechanisms would give
beneficial effect of using L-citrulline to counteract their
pathological activities.
Pathophysiology
of
Oxidative
Stress-induced
Cardiovascular Diseases
Reactive oxygen species are hyperreactive intermediates
of oxygen-related molecules, which are generated
physiologically in mitochondria as byproducts of
oxidative phosphorylation. RNS have similar chemical
characteristics with ROS but with different element
participated, that is nitrogen. Several examples of ROS/
RNS are hydrogen peroxide (H2O2), superoxide anion
(O2-), oxygen nascent (O.), and peroxynitrite (ONOO-).
They are generated as a result of incomplete amounts
of electrons in their atomic valence shell. Destructive
activities of these species, to fulfill their outer electron shell,
are highly related to their oxidative reaction. Oxidation
of nuclear materials, membrane fragmentation, cellular
autolysis, and protein digestion are the devastating ones.
Oxidative stress happens when ROS/RNS levels exceeds
the capability of antioxidant defense system to suppress
them. Cellular ischemia or hypoxia would be the most
dominant factor in triggering oxidative stress. In this
case, myocardial ischemia may happen to cause oxidative
stress. Post-infarct angiogenesis and fibrosis may lead to
ischemic-reperfusion injuries that cause more oxidative
damages within nearby cells. In this way, myocardial
infarction develops other complications as main effects

of cellular oxidative stress (Incalza et al., 2017). Besides
myocardial infarction, cardiac remodeling also induces
oxidative attacks. Excessive cardiac hypertrophy due
to remodeling increased contractility, but with much
lower end-diastolic blood volume. This means that it is
designed to compensate reduced cardiac output due to
aortic stenosis, high cardiac afterload, et cetera. Lower
amount of blood stroked with powerful ventricular
contraction would dramatically decrease the perfusion
of blood into myocardium via coronary arteries. Greater
and greater impact of oxidative stress could gradually
deteriorate cardiac physiology into vicious cycle of heart
failure.
In the situation where cells are experiencing
oxidative stress, formation of peroxynitrite occurs
most. Peroxynitrite is a radical molecule resulted
from the combination of NO and O2- via a pathway
called eNOS uncoupling (Moens et al., 2011). The
‘uncoupling’ mechanism involves decreased amount of
tetrahydrobiopterin (BH4) which normally stabilize the
dimerization of NOS enzyme (Moens et al., 2011). This
structure optimally facilitates the transfer of electron
from NADPH in its reductase domain to heme group
in its oxidase domain to convert arginine into citrulline
by generating NO gas (Tang et al., 2014). Relative
subtraction of BH4 cofactor in NOS is primarily caused
by oxidation of BH4 into dihydrobiopterin (BH2) via
oxidative stress (Moens et al., 2011). As a result, partial
transfer of electrons in non-dimer NOS might lead to
generation of superoxide anion, instead of nitric oxide
(Tang et al., 2014). Further destruction of cells due to
ISSN 2407-2354
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peroxynitrite slowly damage heart pump ability to fulfill
metabolic demands (Tang et al., 2014) eNOS uncoupled
mechanisms can be seen in Figure 9.
Protective Effects of L-citrulline Towards Oxidative
Stress
Because L-citrulline is seen to maintain vascular NO
level, L-citrulline potentially reverses the damaging
effects of oxidative stress in cardiovascular system.
L-citrulline is known to upregulate the expression rate of
normal eNOS enzyme, subsequently compensating for
the uncoupled activity eNOS (Xuan et al., 2015) . NO is
the key modulator of cardiac function through regulation
of myocytes contraction and growth (Tang et al., 2014).
NO activates cGMP signaling cascades that eventually
modifies NOS protein post-translationally by adding
nitrosyl group in free thiol of its cysteine residue (Tang et
al., 2014). Thiol-nitrosylation of cysteine residue firmly
hold the dimer structure of NOS, subsequently reducing
O2- production (Tang et al., 2014). In this condition,
NO could prevent formation of atherosclerotic plaques,
excessive ventricular hypertrophy, as well as pulmonary
arterial hypertension (Van Deel et al., 2015). It also
counteracts complication of hypercholesterolemia and
diabetes mellitus (Moens et al., 2011). Disturbances
in nitroso-redox balance, that tightly controls NO
and O2- level, would finally cause oxidative stress.
eNOS expression levels has been known to linked
with aggravation of left ventricular hypertrophy and
dysfunction in aortic stenosis-induced pressure overload.
Knockout of eNOS gene would increase capillary density,
fibrosis, and natriuretic peptide expression in heart,
rising the risk of cardiac oxidative stress (Van Deel et al.,
2015). L-citrulline is known to reduce systemic arterial
stiffness at rest and aortic pressure responses to coldpressor test. Randomized controlled study of L-citrulline
supplementation could attenuate any exaggerated arterial
stiffness regarding either combined metaboreflex or cold
exposure; thus, this piece of evidence might provide
insight on potential protection against increased cardiac
afterload during physical stress (Figueroa et al., 2016).
Chronic and long-term administration of NO as
prophylaxis would affect vascular tone, or further induce
formation of radical molecules (Xuan et al., 2015). That
is why it would be best to increase NO bioavailability
and balancing nitroso-redox system via NO cycle, using
L-citrulline as substrate. Thus, L-citrulline serves to
protect against cardiovascular disease in the sense of
preventing cellular oxidative stress.
Clinical trials: L-citrulline Towards Cardiovascular
Diseases
Advanced application of L-citrulline has come to major
clinical trials in hospitals. Improvement of six-minute
walking test and quality of life of patients has been seen in
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patients with arterial pulmonary hypertension comorbid
with Eisenmenger syndrome (Sharif et al., 2014) .
Additionally, pre-exercise L-citrulline administration
could enhance splanchnic perfusion, attenuating
intestinal ischemia during strenuous exercise. It prevents
occurrence of oxidative stress in the enterocytes due to
increased number of adequately perfused small vessels
compared to placebo (7.8 ± 6.0 vs. -2.0 ± 2.4, p = 0.06)
(Van Wijck et al., 2014). Further studies include that
assessment of L-citrulline in randomized cross over
clinical trials of thirty patients diagnosed with coronary
artery disease have shown significant improvement
in endothelial function. Ratio flow mediated dilation
(FMD) to nitroglycerin dependent vasodilation (NMD)
in assessing endothelial function increases significantly
conformed with statistical analysis (p < 0.001) after
L-citrulline administration (Safi et al., 2017). Ultimately,
utilization of L-citrulline in experimental clinical group
consisting of 35 patients with systolic heart failure has
successfully improved left ventricular ejection fraction
(LVEF) up to 35% via evaluation though radioisotopic,
ventriculography, and photoplethysmography (Balderas
et al., 2012).
CONCLUSION
Physicians and scientists’ approaches in managing
CVDs regarding strategies’ simplicity, curability, and
preventability had led to using L-citrulline as alternative
pharmacological substance. Chemical characteristics
of L-citrulline are closely related with its biosynthesis
and metabolic processes. It provides wide range of
plasma active dosage with minimal side-effect and is
best administered orally or intravenously to reach its
maximum bioavailability. Furthermore, its antioxidant
capacity would be effective to prevent oxidative stressinduced cardiovascular diseases. eNOS uncoupling,
which produces more radical molecule, could be
reversed by L-citrulline existence. Generating NO gas
through transformation of L-citrulline into arginine in
NO cycle would stabilizes the dimer structure of NOS;
on the other hand, monomer NOS would produce O2as byproducts, instead of NO. Indirectly promoting
vasodilation, reducing pulmonary hypertension, and
regulating of ventricular ejection fraction are all functions
of L-citrulline. Lastly, diverse advantages of L-citrulline
in cardiovascular system is further comprehended to
encourage its utilization in protecting against CVDs.
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